使用活性氧物种作为激活剂的前药物的设计及其在瘤治疗中的应用
Jiaqi Xing1, Wenjuan Lu1, Yubing Zhang1
1State Key Laboratory of Advanced Drug Delivery and Release Systems, Key Laboratory for Biotechnology Drugs of National Health Commission, Key Laboratory of Rare and Rare Diseases in Shandong Province, School of Pharmacy (Institute of Pharmacy) of Shandong First Medical University, Jinan, Shandong 250117, China.
响应活性氧物种 (ROS) 的前药物和纳米输送系统通过向瘤中的高ROS水平,提供精确的癌症治疗. 这些先进的系统增强了药物输送,减少了副作用,并使结合疗法能够改善瘤管理.
科学领域:
- 在瘤学瘤学.
- 材料科学 材料科学 材料科学
- 药物运输 药物运输 药物运输
背景情况:
- 恶性瘤存在重大诊断和治疗挑战.
- 传统化疗由于向不佳,毒性和副作用而存在局限性.
- 癌细胞中活性氧物种 (ROS) 的升高为新型前药物策略提供了目标.
研究的目的:
- 系统地审查对ROS响应的小分子前药物和纳米输送系统的研究.
- 详细阐述基于关键激活机制的设计原则.
- 总结最近的进展和临床应用的未来潜力.
主要方法:
- 在过去五年中对ROS响应性前药物和纳米输送系统 (纳米颗粒,水凝) 的系统性文献综述.
- 分析七个关键激活机制的ROS响应能力.
- 评估与瘤微环境 (TME) 特异性结合的ROS响应能力.
主要成果:
- 响应ROS的系统可以实现精确,可控的药物释放.
- 与传统化疗相比,这些系统显著减少了毒性和副作用.
- 通过组合疗法 (化疗,免疫疗法,光动力疗法) 证明了协同效应.
- 集成的治疗和成像功能允许实时监控药物释放.
结论:
- 响应ROS的前期药物和纳米输送系统对精确的瘤诊断和治疗有很大的前景.
- 这些平台提高了特异性,降低了毒性,并使多模式治疗策略成为可能.
- 进一步开发对于将这些系统推向临床应用至关重要.
更多相关视频
11:04An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model
Published on: January 13, 2023
05:16Author Spotlight: High-Throughput Measurement of Intracellular ROS Levels in Hepatocellular Lines
Published on: January 19, 2024
相关概念视频
Prodrugs
Prodrugs help overcome...
Phase I Oxidative Reactions: Overview
Drug Metabolism: Phase I Reactions
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Drug Metabolism: Phase II Reactions
